Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1996 Oct;9(4):469-88.
doi: 10.1128/CMR.9.4.469.

Virulence factors of medically important fungi

Affiliations
Review

Virulence factors of medically important fungi

L H Hogan et al. Clin Microbiol Rev. 1996 Oct.

Abstract

Human fungal pathogens have become an increasingly important medical problem with the explosion in the number of immunocompromised patients as a result of cancer, steroid therapy, chemotherapy, and AIDS. Additionally, the globalization of travel and expansion of humankind into previously undisturbed habitats have led to the reemergence of old fungi and new exposure to previously undescribed fungi. Until recently, relatively little was known about virulence factors for the medically important fungi. With the advent of molecular genetics, rapid progress has now been made in understanding the basis of pathogenicity for organisms such as Aspergillus species and Cryptococcus neoformans. The twin technologies of genetic transformation and "knockout" deletion construction allowed for genetic tests of virulence factors in these organisms. Such knowledge will prove invaluable for the rational design of antifungal therapies. Putative virulence factors and attributes are reviewed for Aspergillus species, C. neoformans, the dimorphic fungal pathogens, and others, with a focus upon a molecular genetic approach. Candida species are excluded from coverage, having been the subject of numerous recent reviews. This growing body of knowledge about fungal pathogens and their virulence factors will significantly aid efforts to treat the serious diseases they cause.

PubMed Disclaimer

References

    1. Infect Immun. 1972 Jun;5(6):896-901 - PubMed
    1. Infect Immun. 1994 Apr;62(4):1478-9 - PubMed
    1. J Clin Invest. 1993 May;91(5):1979-86 - PubMed
    1. Infect Immun. 1992 Feb;60(2):602-5 - PubMed
    1. Mycopathologia. 1986 Aug;95(2):81-3 - PubMed

Publication types

MeSH terms